CD19 and acute lymphoblastic leukemia: The CAR-T cell therapies Tisagenlecleucel and Axicabtagene ciloleucel were approved by the FDA and the European Medicines Agency in 2017 and 2018, respectively, for the treatment of acute lymphoblastic leukemia, targeting the CD19 antigen on B cells (69).